Intentar ORO - Gratis
India underinvests in science
Express Pharma
|July 2021
Unless we build more than simply two or three global centres of scientific excellence and training, and unless we reward our scientists to work in those institutions, it will be hard for us to compete with countries like China, informs Dr Swami Subramaniam, CEO, Ignite Life Science Foundation to Akanki Sharma in an exclusive interview
Give us a brief about Ignite Life Science Foundation - the story of its origin, its goal and target audience, etc.
Ignite was launched formally at an event in January 2020 but its story had begun prior to that. It is the brainchild of Professor Ramaswamy Subramanian, who was at that time heading C-CAMP in Bengaluru - a part of the Bangalore biocluster. During his working years in India, he recognised many problems Indian scientists were facing and it was not simply a matter of quantum of funding; there were multiple factors.
Research productivity thrives in a complex ecosystem. Very few countries in the world have succeeded in building such self-sustaining ecosystems consisting of multiple factors -government funding, academic institutions (that are often private) that consider research an important purpose for their existence, ability to attract the best students from the global pool, private philanthropists willing to support science through large endowments and the co-existence of research universities with communities of investors, start-ups and large company R&D facilities The Boston-Cambridge (Harvard) area and the San Francisco Bay Area (Stanford), Cambridge University (Cambridge, UK) and the Stockholm area (Stockholm University) are some examples.
Building out such ecosystems takes time, but Rams and his scientific peers got together with leading business persons and academics in India to find Ignite as an organisation that would nurture good science using philanthropic money. Connecting uHNIs to science in Indian universities is the first step towards getting widespread acknowledgement of the challenges facing Indian science and pooling resources and capabilities to solve some of these challenges - funding is only one among those.
Esta historia es de la edición July 2021 de Express Pharma.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Express Pharma
Express Pharma
Speed and flexibility play a critical role in how we compete with larger global players
Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma
6 mins
January 2026
Express Pharma
Vizag rising: Shaping India's pharma future
At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth
9 mins
January 2026
Express Pharma
Future of pharma: Trends, challenges & AI
Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies
2 mins
January 2026
Express Pharma
Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments
When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.
1 mins
January 2026
Express Pharma
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare
3 mins
January 2026
Express Pharma
The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.
6 mins
January 2026
Express Pharma
Results win customers. Leadership discipline keeps them
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
3 mins
January 2026
Express Pharma
INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF
India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge
8 mins
January 2026
Express Pharma
PRUV® -The original Sodium Stearyl Fumarate
JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago
5 mins
January 2026
Express Pharma
Odisha's pharma pitch
The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury
5 mins
January 2026
Translate
Change font size
